DeciBio Culture

The first edition of this report provides an overview of the pharma R&D services market from 2024 to 2029. These service providers deliver specialized expertise, infrastructure, and support across the drug development lifecycle. While the ecosystem includes hundreds of vendors, the level of fragmentation varies by stage. Clinical trial services are relatively consolidated, with leaders such as ICON, IQVIA, Thermo Fisher Scientific (via PPD), and WuXi AppTec. Preclinical services are often dominated by vendors with GLP/GMP capabilities, such as Charles River Laboratories. In contrast, discovery stage research and bioinformatics services remain more fragmented, allowing pharma companies to engage a wider range of niche or specialized partners.

This report provides a summary of oncology genomics testing practices, oncologist perspectives and experiences with test providers, and expected future utilization behaviors. A subscription to this report includes 4 waves of data, collected on a quarterly basis (4 reports total, delivered once a quarter).

The eighth edition of this report provides an overview of the life sciences research tools (LSRT) market from 2019 to 2029. LSRT companies offer instruments, reagents and services to academic, biopharma, applied market, and (non-IVD) clinical customers. While the LSRT space includes hundreds of companies, the market is relatively consolidated, with top vendors including Agilent, Becton Dickinson, Danaher, Illumina, Merck-EMD Millipore, and (most notably) Thermo Fisher representing the majority of sales; however, mid-size players (e.g., PacBio) and smaller emerging players (e.g., Element, Quantum-Si) are often growing more rapidly, and driving innovation.

DeciBio conducted 16 interviews with U.S. biopharma and CDMO stakeholders to understand key trends in the development and manufacturing of oligo therapeutics today.